Leonteq Securities AG Purchases Shares of 195,000 Iovance Biotherapeutics, Inc. $IOVA

Leonteq Securities AG purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 195,000 shares of the biotechnology company’s stock, valued at approximately $532,000.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Iovance Biotherapeutics by 13.1% during the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after purchasing an additional 3,148,096 shares during the period. Invenomic Capital Management LP grew its stake in shares of Iovance Biotherapeutics by 27.1% during the 3rd quarter. Invenomic Capital Management LP now owns 10,541,608 shares of the biotechnology company’s stock valued at $22,875,000 after purchasing an additional 2,246,945 shares during the period. Palo Alto Investors LP lifted its position in shares of Iovance Biotherapeutics by 122.1% during the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after buying an additional 4,188,803 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Iovance Biotherapeutics by 55.8% during the 3rd quarter. Bank of America Corp DE now owns 6,279,230 shares of the biotechnology company’s stock valued at $13,626,000 after buying an additional 2,249,662 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after buying an additional 3,869,617 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors.

Iovance Biotherapeutics Stock Up 11.1%

IOVA stock opened at $4.11 on Friday. The business’s 50-day moving average price is $3.63 and its 200-day moving average price is $3.04. Iovance Biotherapeutics, Inc. has a twelve month low of $1.66 and a twelve month high of $5.63. The stock has a market cap of $1.84 billion, a P/E ratio of -4.33 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The company had revenue of $71.43 million for the quarter, compared to analysts’ expectations of $77.84 million. During the same period in the previous year, the firm earned ($0.36) EPS. The firm’s revenue was up 44.9% compared to the same quarter last year. On average, equities research analysts expect that Iovance Biotherapeutics, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IOVA has been the topic of a number of analyst reports. Citizens Jmp raised Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective on the stock in a research report on Tuesday, March 3rd. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Monday, April 6th. Wall Street Zen raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, UBS Group lifted their price objective on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $8.43.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.